Aurora Cannabis Inc.

NasdaqCM:ACB 주식 리포트

시가총액: US$209.5m

Aurora Cannabis 향후 성장

Future 기준 점검 0/6

Aurora Cannabis은 연간 수입과 매출이 각각 90.8%와 0.7% 증가할 것으로 예상되고 EPS는 연간 76.8%만큼 증가할 것으로 예상됩니다.

핵심 정보

90.8%

이익 성장률

76.83%

EPS 성장률

Pharmaceuticals 이익 성장14.5%
매출 성장률0.7%
향후 자기자본이익률n/a
애널리스트 커버리지

Low

마지막 업데이트05 May 2026

최근 향후 성장 업데이트

Recent updates

Seeking Alpha Nov 06

Aurora Cannabis: Upgrading On High-Margin Medical Cannabis Sales Growth - Buy

Summary Aurora Cannabis reported Q2/FY2026 results largely in line with expectations previously outlined by management. High-margin medical cannabis revenue increased by 15% year-over-year and 9% quarter-over-quarter, driven by strong sales in Germany and Poland. On the flip side, sales in Australia declined for a second consecutive quarter due to increasing competition. The disappointing performance resulted in the requirement to take a sizeable impairment charge. While not everything is going according to plan, management remained constructive on the company's near-term outlook and guided for record Adjusted EBITDA in Q3. As a result, I am increasing my price target from $5.65 to $6.30. Given more than 40% upside from current levels and expectations for solid growth in medical cannabis sales, I am upgrading the stock from "Hold" to "Buy". Read the full article on Seeking Alpha
Seeking Alpha Feb 22

Aurora Cannabis: This Phoenix Has Risen From The Ashes (Strong Buy Initiation)

Summary Aurora Cannabis has transformed its margins, market position, and balance sheet over the last few years, and the stock is now highly 'investible'. ACB's strategic focus on the global medical cannabis market has led to gross margin growth and reduced competition, enhancing top and bottom-line results. The stock is trading at an extremely attractive multiple, and we see significant upside if ACB continues to execute and market awareness of the story improves. We initiate coverage on ACB with a 'Strong Buy' rating. Read the full article on Seeking Alpha
Seeking Alpha Aug 08

Aurora Cannabis: Revving Up To Profitability

Summary Aurora Cannabis achieves milestone positive free cash flow for the first time in Q1 FY2025. Strong growth in medical cannabis, particularly in Australia and Europe, positions the company well for future profitability. Potential US rescheduling of cannabis could impact Aurora's stock price and open up opportunities in the US market. Read the full article on Seeking Alpha
Seeking Alpha Oct 17

Aurora launches new cannabis products for adult and medical-use

Aurora Cannabis (NASDAQ:ACB) is trading ~2% higher after it announced its fall lineup of cannabis products. The products include three unique and proprietary strains -Electric Honeydew, Ultra Grape Kush and Organic BC White Grape OG. The fall product release is set to roll out to patients on Aurora Medical starting in October. "This extensive line up of flower innovation was made possible from Aurora's differentiated consumer preference mapping, which uniquely plots evolving cannabis preferences, and the leading work of R&D to develop a portfolio of products with the critical components necessary to compete – intense and exciting aromas, key visual and tactile attributes, and high-potency THC," the company said.
Seeking Alpha Oct 07

Aurora Cannabis further strengthens its balance sheet by repurchasing ~US$23M of convertible notes

Aurora Cannabis (NASDAQ:ACB) has repurchased approximately C$31.3M (US$23M) principal amount of its convertible senior notes at a 5.45% discount to par value, at a total cost, including accrued interest, of C$29.8M in cash. The purpose of the transaction was to reduce the company's debt and annual cash interest costs. Annual cash interest savings from the repurchases of notes made from Q3 2022 onwards now total approximately C$11.9M. The company's balance sheet remains amongst the strongest in the industry, with approximately $380M of cash and cash equivalents. The company reiterates its expectation of achieving a positive Adjusted EBITDA run rate by December 31, 2022. Shares up 4.5% PM. Also read: Tilray and other cannabis stocks soar as Biden calls for marijuana scheduling review
Seeking Alpha Sep 19

Aurora Cannabis Q4 2022 Earnings Preview

Aurora Cannabis (NASDAQ:ACB) is scheduled to announce Q4 earnings results on Monday, September 19th, before market open. The consensus EPS Estimate is -$0.12 and the consensus Revenue Estimate is $38.16M Over the last 3 months, EPS estimates have seen 1 upward revision and 0 downward. Revenue estimates have seen 0 upward revisions and 3 downward.  In Q3,  the company boosted it target for annual expenses to C$150M-C$170M by 1H 2023, up from C$60M-$C-80M before. Last quarter, the company saw its Q3 2022 EBITDA net loss narrow 41% to C$12.3M compared to the prior-year period despite a decrease in net revenue. Also Read- Non-medical cannabis sales rose 21% YTD in Canada - Cantor
Seeking Alpha Aug 25

Aurora Cannabis: Don't Let Your Money Go Up In Smoke

Summary Aurora Cannabis has been dead money for years, and the trend is bound to continue. Company is bleeding cash and there's no immediate solution in sight for the impending liquidity problems. We are not happy with the recent acquisition given the declining fundamentals. Expected political changes will provide no catalyst for the stock going forward. Thesis With the recent acquisition, Aurora Cannabis (ACB) is even more of a stock for investors to avoid. The company has historically reported poor financial results despite major acquisitions, and the company is burning through cash rapidly as loan commitments are coming due. We believe that liquidity issues and an unfavorable political environment in the United States will continue to drive this stock price lower over the coming years. Company Overview Aurora Cannabis is a cannabis growing company based in Edmonton, Canada. Aurora operates a network of subsidiaries related to the cannabis industry, and the company owns numerous brands, such as San Rafael '71, Daily Special, CanniMed, Whistler Cannabis Co., and more. These brands create cannabis products for consumer and medical consumption. The stock has had abysmal return for investors, and the stock trades at around $1.675 compared to its historic high above $120 per share only a few years ago. The company now has a valuation of less than $500 million CAD. ACB data by YCharts Abysmal Performance and Returns Aurora Cannabis has had poor financial performance in line with the poor stock price performance in the same time frame. The company is still down ~80% from its 52-week high of $8.69 and the stock price is correlated with the revenue decline. For a growth stock name, the company has actually seen its revenue decline over the past few years, even as the company aggressively acquired competitors. For the recent quarter, revenue has declined 9% YoY and has declined 17% QoQ. In addition, the company has reported a loss of $1 billion CAD in the recent quarter, and according to a report, the recent quarter increased the cumulative net losses of the company to roughly $5.3 billion CAD since 2015. These losses are astronomical, given that the cumulative losses are now 10x the current market capitalization of the company. The poor financial performance should immediately be a red flag to investors, and we believe that there is no immediate catalyst to turn this stock around anytime soon. ACB data by YCharts Liquidity Issues For a company with such large losses, it is not hard to find that the company is exposed to major liquidity issues. In the most recent FY 2021 financial report, the company outlines that ~$494 million CAD are liabilities that are payable between one and three years. In that same time frame, the company reported that there's $332.4 million CAD in cash and cash equivalents, which is substantially below the pending commitments in the next few years. Given the liabilities and the negative earnings, liquidity is risk of the utmost issue, and it is unclear how management plans to navigate through this problem. ACB FY 2021 We believe given management's history, we find it likely that the management will continue to keep the business afloat through dilutive actions and tapping into the debt markets, which will only further add debt to the unprofitable business. As seen below, the diluted shares outstanding for ACB has soared as a result of various acquisitions and financing needs. Just recently, the company announced a major acquisition at a price tag of ~$45 million CAD in cash. Regardless of the potential synergies through the acquisition, we find that the cash burn in addition to constant acquisitions are not recipes for success when the company's fundamentals continue to decline. We don't see that this trend will stop any time soon, and we believe that the company should be avoided at all costs as a result of its frivolous spend and impending liquidity crunch. ACB Average Diluted Shares Outstanding (Annual) data by YCharts Upcoming Political Headwinds
Seeking Alpha Jun 13

Why Did Aurora Cannabis Stock Crash In May; Can It Recover?

Aurora Cannabis plunged 54% at the end of May. This was due to an expensive bought deal offering that came even as the company boasted a net cash position. Management has guided for positive adjusted EBITDA within 3 quarters. The stock is cheap relative to Canadian peers.
Seeking Alpha May 13

Recent Developments Do Not Change Our Stance On Aurora Cannabis

Aurora Cannabis reported decent numbers for the third quarter of fiscal 2022. The company continues to focus on cost savings, which is the latest strategy adopted by Aurora to boost short-term earnings. The recent developments do not materially change our view on Aurora for reasons discussed in this analysis.
Seeking Alpha May 05

Aurora Cannabis: A Train Wreck Desperate For Help

Aurora Cannabis is set to release its third quarter earnings on Thursday, May 12, after market close. Last month, the House passed a bill that is set to legalize cannabis on a federal level, it being one of the few positive catalysts going for the company. Management of Aurora has been sued multiple times, including class-action lawsuits due to misleading investors. Since inception, there has been a dilution of over 96%, with high cash burn and no clear end in sight.
Seeking Alpha Feb 17

Aurora Cannabis: The Fallen Pot Giant That Still Can't Find Its Way

The Canadian cannabis retail market has become oversaturated with producers, imposing pricing pressures and making mistakes more costly. ACB is still reeling from its overspending on acquisitions as it tries to cut OPEX as part of its 2020 business transformation plan. The FY22 Q2 earnings call reported a 10% drop in revenue from the year prior, with much of this loss coming from a 48% decrease in retail cannabis revenue. ACB's management is still failing to unite behind a focused strategy and will continue to fail until they do.

이익 및 매출 성장 예측

NasdaqCM:ACB - 애널리스트 향후 추정치 및 과거 재무 데이터 (CAD Millions)
날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수
3/31/2029351N/AN/AN/A1
3/31/2028348N/A49613
3/31/2027323-1867295
3/31/2026358-7925405
12/31/2025373-84-31-10N/A
9/30/2025367-57-182N/A
6/30/2025358-3-118N/A
3/31/202534316-316N/A
12/31/202432015-29-9N/A
9/30/2024296-29-61-43N/A
6/30/2024278-30-67-49N/A
3/31/2024270-53-85-69N/A
12/31/2023266-108-91-71N/A
9/30/2023262-153-145-127N/A
6/30/2023248-195-141-127N/A
3/31/2023224-793-163-142N/A
12/31/2022212-1,748-181-157N/A
9/30/2022210-1,757-152-118N/A
6/30/2022221-1,718-142-110N/A
3/31/2022226-1,233-98-64N/A
12/31/2021231-381-122-82N/A
9/30/2021238-607-165-124N/A
6/30/2021245-692-264-211N/A
3/31/2021257-2,387-357-284N/A
12/31/2020275-2,359-430-285N/A
9/30/2020263-3,342-614-357N/A
6/30/2020269-3,231-691-342N/A
3/31/2020299-1,405-778-293N/A
12/31/2019291-1,430-787-289N/A
9/30/2019290-385N/A-218N/A
6/30/2019246-294N/A-192N/A
3/31/2019168-211N/A-233N/A
12/31/2018119-72N/A-206N/A
9/30/201877174N/A-146N/A
6/30/20185572N/A-82N/A
3/31/201842-13N/A-35N/A
12/31/2017317N/A-16N/A
9/30/201723-4N/A-15N/A
6/30/201718-13N/A-13N/A
3/31/201713-16N/A-17N/A
12/31/20168-13N/A-11N/A
9/30/20165-10N/A-9N/A
6/30/20161-6N/A-7N/A
3/31/201600N/A-5N/A
12/31/2015N/A-3N/A-3N/A
9/30/2015N/A-10N/A-3N/A

애널리스트 향후 성장 전망

수입 대 저축률: ACB 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: ACB 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: ACB 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: ACB 의 수익(연간 0.7%)이 US 시장(연간 11.7%)보다 느리게 성장할 것으로 예상됩니다.

고성장 매출: ACB 의 수익(연간 0.7%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.


주당순이익 성장 예측


향후 자기자본이익률

미래 ROE: ACB의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.


성장 기업 찾아보기

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2026/05/26 16:14
종가2026/05/22 00:00
수익2025/12/31
연간 수익2025/03/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Aurora Cannabis Inc.는 17명의 분석가가 다루고 있습니다. 이 중 5명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
Frederico Yokota Choucair GomesATB Cormark
Tamy ChenBMO Capital Markets Equity Research
Etienne RicardBMO Capital Markets Equity Research